NICE recommends zanubrutinib for CLL
Standard post… comes back ( relapses ) or doesn’t respond to treatment ( refractory ). Zanubritinib is a type of targeted treatment …
Top of page
New treatment approval for CLL
Standard post… with CLL that has come back (relapsed) or not responded (refractory) after at least one previous course of treatment. …
Ron
Standard post… non-Hodgkin lymphoma when a person has relapsed or has refractory disease (where treatments are no longer working). … the addition of another drug for people with relapsed or refractory lymphoma.’ October 2016 … The challenges of …
US trial of 'off-the-shelf' CAR-T cell therapy
Standard post… that has come back (relapsed) or has not responded (refractory) after previous treatment. To find out more about …
CAR T-cell therapy to be available on the NHS for people with lymphoma
Standard post… therapy available on the NHS for people with relapsed or refractory large cell lymphomas, such as diffuse large B-cell …
New treatment for T-cell skin lymphoma approved in Scotland
Standard post… advanced T-cell skin lymphomas who have not responded ( refractory ) or whose lymphoma has come back ( relapsed ) …
NuTide:701: a phase 1 trial to find the best dose and test the safety of a new drug called NUC-7738 in people with advanced solid tumours or lymphoma
Trial… have come back after (relapsed), or not responded to (refractory) treatment may be eligible for this trial. …
CO43805: A Phase 1b trial of mosunetuzumab or glofitamab in people with B-cell Non-Hodgkin Lymphoma
Trial… the future. Who can enter Anyone over 18 with relapsed or refractory B cell NHL who have previously received at least …
MOGAT: A phase 2 trial of mogamulizumab in cutaneous T-cell lymphoma
Trial… have failed at least one prior course of systemic therapy (refractory disease) or who have relapsed may be eligible for …
BGB-11417 (BCL): A phase 1 trial of BGB-11417 in people with B cell malignancies
Trial… or obinutuzumab. It will be aimed at people with refractory or relapsed B cell lymphomas who have failed to …